Annovis Bio Makes Strides in Neurodegenerative Disease Treatment: 2023 Q4 Results Below Projections, Progress Seen in Clinical Trials

14d ago, source: MyChesCo on MSN

In a recent financial report for 2023, Annovis Bio, Inc. (NYSE: ANVS) proclaimed progress in the battle against ...

Annovis Bio's Buntanetap Shows Promise in Early Alzheimer’s Disease Study

15d ago, source: MyChesCo on MSN

In a significant development for Alzheimer’s Disease (AD) research, Annovis Bio, Inc. (NYSE: ANVS) has unveiled new data from ...

Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results

16d ago, source: Business Insider

MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative ...

Annovis Bio Inc (ANVS): A Technical Analysis

5mon ago, source: newsheater

The stock price of Annovis Bio Inc (NYSE: ANVS) has dropped by -9.11 compared to previous close of 11.09. Despite this, the company has seen a fall of -12.27% in its stock price over the last five ...

Annovis Announces Publication That Supports Understanding of Buntanetap's Mechanism of Action in Humans

17d ago, source: TMCnet

Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced the publication of new data from an earlier study ...

DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch

14h ago, source:

DiaMedica (DMAC) rises 10% as it doses the first patient in the relaunch of its pivotal study evaluating the lead candidate, DM199, to treat acute ischemic stroke.

Eyenovia (EYEN) Down 18% on Disappointing Corporate Update

9d ago, source:

Eyenovia (EYEN) plunges 18% after sharing plans to consider strategic alternatives involving the sale of the company or assets, amid a severe cash crunch and poor performance of marketed drugs.

Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study

2d ago, source: Zacks.com on MSN

Ultragenyx (RARE) reports positive interim data from the phase I/II study of GTX-102 for Angelman syndrome. However, the ...